Efficacy and safety of the artemisinin combination therapy (ACT) in uncomplicated falciparum malaria patients in Myanmar and artemisinin molecular markers analysis
The investigators assessed the efficacy and safety of the ACT in uncomplicated falciparum malaria in different sentinel sites in Myanmar. The recruited patients were follow-up until day 28 or day-42 based on the ACTs. Day-0 samples were analysed for artemisinin molecular markers, (K13 kelch propeller, Pfmdr2, Pffd and Pfarps10).
Study Type
OBSERVATIONAL
Enrollment
550
Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
Dr. Myat Phone Kyaw
Yangon, Yangon, Burma
Proportion of adequate clinical and parasitological response (ACPR)
For artesunate-mefloquine or dihydroartemisinin-piperaquine, 42 days follow-ups and for artemether-lumefrantrine combinations, 28 days followe-ups
Time frame: day 28 or day 42 after initial dose of ACT
Proportion of the day-3 parasite positivity after ACT by microscopy
72 hr after ACT is one of the indicator for delayed clearance of parasitaemia in falciparum malaria
Time frame: 3rd day after initial dose of ACT
Treatment failure rate
Early Treatment Failure (ETF), Late Clinical Failure (LCF), Late Parasitological Failure (LPF) based on the WHO standard protocol and definitions
Time frame: anytime within observation period (28/42 days after treatment with one of ACTs)
Mutant rate
Day-0 samples were used to amplify the artemisinin resistance molecular markers to know the mutant rate in each study sites
Time frame: Day-0 samples
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.